NASDAQ
4.33USD
-0.18 (-3.99%)
We have scored 3 news catalysts on Zura Bio Limited (ZURA) over the past 12 months. The biggest single-day move next to one of them came Jul 19, 2026, when ZURA closed +3.8%: “Simmons First National (NASDAQ:SFNC) Sees Large Volume Increase – Here’s Why”. Coverage across the window leans positive (average ticker sentiment +0.57). Most of the impact sits in price momentum and earnings revision trend.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
411.3M
P/E
—
EPS
—
Beta
-0.04
52W range
2.011-7.44
Day range
4.16–4.53
Open
4.53
Prev close
4.51
Volume
2.1M
Avg volume
1.3M
Dividend
0.00
IPO
2023-03-21
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Zura Bio Limited — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ZURA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
